Sandoz’s South African Plant Fails World Health Organization Inspection
Executive Summary
Sandoz has once again been hit with a negative review of one of its manufacturing plants
You may also be interested in...
GMP Warning To Sandoz Questions Continued Lot Release; Will FDA Block It?
FDA's warning letter to Sandoz over violations of good manufacturing practices suggests the agency is taking a stronger, but still measured, tone in its GMP oversight
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.